Stockreport

Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates [Yahoo! Finance]

Lantern Pharma Inc.  (LTRN) 
PDF LP-184 Phase 1a clinical trial results demonstrate all primary endpoints achieved with 48% clinical benefit rate in evaluable cancer patients at or above therapeutic do [Read more]